SCHEMBL4526571

SCHEMBL4526571

O=S(=O)(c1ccc(F)cc1)C1CNCC[N]1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 2/20 0.37
HTR2B P41595 2/20 0.37
HTR6 P50406 7/20 0.36
PTGS2 P35354 1/20 0.34
MMP3 P08254 1/20 0.33
MMP10 P09238 1/20 0.33
MMP2 P08253 2/20 0.33
AKR1B1 P15121 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
MMP1 P03956 1/20 0.33
MMP9 P14780 1/20 0.33
MMP8 P22894 1/20 0.33
MMP13 P45452 1/20 0.33
KMT2A Q03164 2/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
PKM P14618 1/20 0.32
CYP11B1 P15538 1/20 0.32
CYP11B2 P19099 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9940358 0.84 GAA (0.37) HTR6CA1CA2KMT2APKM
SCHEMBL5360280 0.84 ALDH1A1 (0.35) HTR2CHTR2BHTR6ALDH1A1
SCHEMBL9131888 0.76 HTR6 (0.40) HTR2CHTR2BHTR6AKR1B1
SCHEMBL20002842 0.72 HTR6 (0.44) HTR2CHTR2BHTR6PTGS2CYP11B1
SCHEMBL28243003 0.72 HTR6 (0.44) HTR2CHTR2BHTR6PTGS2CYP11B1
SCHEMBL1616732 0.71 KDM1A (0.38)
SCHEMBL10799201 0.70 APLNR (0.47) HTR2CHTR2BHTR6PTGS2MMP2
Hydrochloric Acid SCHEMBL10800269 0.69 APLNR (0.46) HTR2CHTR2BHTR6PTGS2
SCHEMBL5212828 0.68 CYP11B1 (0.49) HTR2CHTR2BHTR6PTGS2LMNA
SCHEMBL334411 0.68 HTR6 (0.45) HTR6AKR1B1CA1CA2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090203577-A1 Azepinoindole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2009-08-13 US claimed
EP-1963331-A1 AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS Exelixis, Inc. (US) 2008-09-03 EP claimed
WO-2007070796-A1 AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS, INC. (US) 2007-06-21 WO claimed
US-20090203577-A1 Azepinoindole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2009-08-13 US disclosed
EP-1963331-A1 AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS Exelixis, Inc. (US) 2008-09-03 EP disclosed
WO-2007070796-A1 AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS, INC. (US) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203577-A1 Azepinoindole Derivatives As Pharmaceutical Agents NR1H4, NR1I2, GPBAR1 HTR2C 230/4885HTR2B 510/4885HTR6 463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.